Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
Transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) have critical roles in regulating the metastasis of aggressive breast cancers, yet the impact of epithelial-mesenchymal transition (EMT) induced by TGF-β in altering the response of breast cancer cells to EGF remains unknown. We show in this study that murine metastatic 4T1 breast cancer cells formed compact and dense spheroids when cultured under three-dimensional (3D) conditions, which was in sharp contrast to the branching phenotypes exhibited by their nonmetastatic counterparts. Using the human MCF10A series, we show that epithelial-type and nonmetastatic breast cancer cells were unable to invade to EGF, whereas their mesenchymal-type and metastatic counterparts readily invaded to EGF. Furthermore, EMT induced by TGF-β was sufficient to manifest dense spheroid morphologies, a phenotype that increased primary tumor exit and invasion to EGF. Post-EMT invasion to EGF was dependent on increased activation of EGF receptor (EGFR) and p38 mitogen-activated protein kinase, all of which could be abrogated either by pharmacologic (PF-562271) or by genetic (shRNA) targeting of focal adhesion kinase (FAK). Mechanistically, EMT induced by TGF-β increased cell-surface levels of EGFR and prevented its physical interaction with E-cadherin, leading instead to the formation of oncogenic signaling complexes with TβR-II. Elevated EGFR expression was sufficient to transform normal mammary epithelial cells, and to progress their 3D morphology from that of hollow acini to branched structures characteristic of nonmetastatic breast cancer cells. Importantly, we show that TGF-β stimulation of EMT enabled this EGFR-driven breast cancer model to abandon their inherent branching architecture and form large, undifferentiated masses that were hyperinvasive to EGF and showed increased pulmonary tumor growth upon tail vein injection. Finally, chemotherapeutic targeting of FAK was sufficient to revert the aggressive behaviors of these structures. Collectively, this investigation has identified a novel EMT-based approach to neutralize the oncogenic activities of EGF and TGF-β in aggressive and invasive forms of breast cancer.
Wendt
M K
MK
Division of General Medical Sciences--Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Smith
J A
JA
Schiemann
W P
WP
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D015820:Cadherins / Q000378:metabolism; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary; D045744:Cell Line, Tumor; D004815:Epidermal Growth Factor / Q000378:metabolism* / Q000494:pharmacology; D058750:Epithelial-Mesenchymal Transition; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D034741:RNA, Small Interfering / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000378:metabolism* / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D015820:Cadherins; D007211:Indoles; C527797:N-methyl-N-(3-((2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl)-pyridin-2-yl)-methanesulfonamide; D034741:RNA, Small Interfering; D018125:Receptors, Transforming Growth Factor beta; D013449:Sulfonamides; D016212:Transforming Growth Factor beta; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D051416:Focal Adhesion Protein-Tyrosine Kinases; D048051:p38 Mitogen-Activated Protein Kinases
Cancer Res. 2007 Apr 15;67(8):3752-8
17440088
Cancer Cell. 2009 Aug 4;16(2):91-102
19647220
Clin Exp Metastasis. 2008;25(8):843-54
18696232
Cancer Sci. 2007 Oct;98(10):1512-20
17645776
Cancer Res. 2005 Oct 15;65(20):9455-62
16230409
Neoplasia. 1999 Dec;1(6):508-17
10935498
J Cell Physiol. 2007 Nov;213(2):374-83
17680632
Exp Cell Res. 1996 Jul 10;226(1):214-22
8660958
J Clin Invest. 2009 Sep;119(9):2678-90
19726885
BMC Cancer. 2007 Jul 24;7:134
17650314
Cell. 2008 Apr 4;133(1):66-77
18394990
Oncogene. 2005 Aug 29;24(37):5764-74
16123809
Mol Oncol. 2007 Jun;1(1):84-96
18516279
Breast Cancer Res. 2006;8(4):R42
16859511
Cancer Res. 2008 Mar 15;68(6):1935-44
18339875
J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):99-102
18769505
J Clin Invest. 2009 Jun;119(6):1420-8
19487818
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
12829800
Future Oncol. 2009 Oct;5(8):1145-68
19852727
Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10290-5
19502425
J Biol Chem. 2008 Oct 3;283(40):26839-49
18669633
Clin Exp Metastasis. 2008;25(6):685-93
18236164
Oncogene. 2006 Jul 27;25(32):4429-40
16547501
Exp Cell Res. 2008 Jan 1;314(1):143-52
17949712
Nat Cell Biol. 2000 May;2(5):249-56
10806474
J Biol Chem. 2009 Dec 4;284(49):34145-56
19822523
Nature. 2000 Aug 17;406(6797):747-52
10963602
Cancer Res. 2009 Jan 15;69(2):475-82
19147560
J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36
7806579
Mol Endocrinol. 2007 Dec;21(12):2907-18
17761946
Dev Cell. 2008 Jun;14(6):818-29
18539112
Future Oncol. 2009 Mar;5(2):259-71
19284383
Oncogene. 2008 Feb 28;27(10):1461-71
17724466
Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1
16024596
Cancer Res. 2008 Feb 1;68(3):707-14
18245470
J Cell Physiol. 1987 Mar;130(3):397-409
3494020
Cell Mol Life Sci. 2000 Jan 20;57(1):41-64
10949580
Cell. 2009 Nov 25;139(5):871-90
19945376
Breast Cancer Res. 2009;11(5):R68
19740433
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Cancer Res. 2004 Oct 1;64(19):7022-9
15466195
Mol Med Today. 2000 Aug;6(8):324-9
10904250
Cancer Res. 2000 Oct 1;60(19):5401-4
11034079
Cancer Res. 1992 Mar 15;52(6):1399-405
1540948
Cancer Res. 1996 Nov 15;56(22):5285-92
8912870
Mol Cancer Ther. 2007 Feb;6(2):532-41
17308052
Mol Cell Biol. 2008 Sep;28(18):5605-20
18625725
Oncogene. 2008 Jan 24;27(5):614-28
17637750